NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Health Information Services · USD

Aclarion, Inc. (ACON) Stock Analysis

Aclarion, Inc. (ACON) is a Health Information Services stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

ACON

$1.95

−$0.02 (−1.02%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ACON with… →

ACON Key Statistics

As of Oct 21, 2026
Trading
Open
$1.95
Previous Close
$1.97
Day's Range
1.92–1.97
52-Week Range
1.85–9.36
Volume
10.24K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.21
Valuation
Market Cap
$5.62M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
67.10
EPS (ttm)Profit attributable to each share over the last twelve months.
−7.38
Financials (FY)
Revenue (FY)
$75.73K+65.62%
Net Income (FY)
−$7.23M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
2.88M
1-Year Return
−75.13%
Dividend and dates
Avg Volume
51.08K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, ACON closed at $1.95, −75.13% over 1 year.

Aclarion, Inc. (ACON) has a market capitalization of $5.62M.

In fiscal 2025, ACON reported revenue of $75.73K.

ACON Stock Return by Calendar Year

Aclarion, Inc. (ACON) return since Apr 2022: what $10,000 became

1 year
$10,000 $2,487
−75.13%
3 years
$10,000 $0.24
−99.998%
Since Apr 2022
$10,000 $0.05
−99.9995%

If you had invested $10,000 in Aclarion, Inc. (ACON) at the close on April 22, 2022, the earliest close on record here, it would have been worth $0.05 at the close on October 21, 2026: −99.9995% in total, −93.38% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−57.61%
2025−99.65%
2024−95.50%
2023−65.52%
2022 (partial year)−78.68%

As of October 21, 2026.

ACON Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$75.73K−$7.23M−9,551.9%
2024$45.72K−$6.99M−15,293.8%
2023$75.40K−$4.91M−6,513.4%
2022$60.44K−$7.07M−11,694.4%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$75.73K$6.83K−$7.05M−$7.23M−9,551.9%
2024$45.72K−$38.93K−$5.51M−$6.99M−15,293.8%
2023$75.40K−$324.00−$4.88M−$4.91M−6,513.4%
2022$60.44K−$4.85K−$5.56M−$7.07M−11,694.4%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ACON Valuation vs Health Information Services Median

Median of 44 stocks
MetricACONHealth Information Services medianvs median
P/S ratio67.102.3129.1x the median

Medians across 44 Health Information Services stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 9 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Aclarion, Inc. (ACON) at $5.62M. It is classified in the Health Information Services industry, within the Healthcare sector. The company reports 10 employees.

The most recent close on file for ACON is $1.95, dated October 21, 2026. That is −$0.02 (−1.02%) against the previous close. Over the past 52 weeks the price has ranged from $1.85 to $9.36. The latest close sits 5.41% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $75.73K. That is +65.62% against the prior fiscal year, when revenue was $45.72K. The same year closed with a net loss of $7.23M. Trailing earnings per share are −7.38.

Across the 4 fiscal years on file, revenue moves from $60.44K in 2022 to $75.73K in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 67.1 times revenue. On price-to-sales that is 29.1 times the Health Information Services median of 2.31. 44 Health Information Services companies report these metrics, and the medians quoted come from that group.

Beta against the wider market is reported at 1.21. Daily returns over the trailing 4 years annualize to a volatility of 170.14%. Over the trailing twelve months the total return is −75.13%. Measured over 3 years, that is −97.12% a year compounded.

Growth & Income

The record shows no dividend for ACON.

So far in 2026 the total return is −57.61%. Across the complete calendar years on file, 2023 returned −65.52% and 2025 returned −99.65%. Of the 3 complete calendar years on file, 0 finished higher.

Peer Comparison

Aclarion, Inc. (ACON) operates in the Health Information Services industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Aclarion, Inc. ACON $5.62M —
Veeva Systems Inc. VEEV $51.90B 52.6
BrightSpring Health Services, Inc. BTSG $12.40B 55.4
Tempus AI, Inc. TEM $12.23B —

The Health Information Services industry average P/E ratio is 46.5x. Aclarion, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Health Information Services Stocks

VEEV

Veeva Systems Inc.

$51.90B

 BTSG

BrightSpring Health Services, Inc.

$12.40B

 TEM

Tempus AI, Inc.

$12.23B

 HNGE

Hinge Health, Inc.

$9.04B

 HQY

HealthEquity, Inc.

$8.10B

 DOCS

Doximity, Inc.

$5.99B
View all Health Information Services stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Aclarion, Inc.

Aclarion, Inc. operates as a healthcare technology company in the United States. It uses magnetic resonance spectroscopy (MRS) combined with proprietary signal-processing biomarkers to optimize clinical treatments. The company develops NOCISCAN, which uses MRS capabilities to non-invasively analyze the chemical makeup of intervertebral discs in the spine. It also provides NOCISCAN MRS Exam Protocol, a custom software protocol for using commercially available MRS pulse sequences in scanning intervertebral discs which extends the time of a standard lumbar MRI exam; and imaging data transfer products, including AMBRA Healthcare, a data transfer platform. In addition, the company offers The NOCISCAN Post-Processor Suite comprising NOCICALC, a Class I medical device that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra, and performs various degenerative pain biomarker calculations from those spectra, for each disc examined; and NOCIGRAM, which further processes the NOCICALC results into individual NOCISCORES, on a 0-10 scale, that represent the different relative levels of degenerative pain biomarkers the various discs examined in the patient. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.

Visit website →